Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies.

By L. Lard, H. Visser, I. Speyer, I. E. V. Horst-Bruinsma, Aeilko H. Zwinderman, F. Breedveld, J. Hazes. American Journal of Medicine, 2001

643 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Treating rheumatoid arthritis to target: recommendations of an international task force (2010, positive): “21 22 26 Third, newly licensed medications, especially biological agents, have enabled the attainment of unprecedented outcomes.”
Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. (2004, result): “Fourthly, the frequencies of patients with erosive disease increased by around 50% during the 3 yr of observation in both groups, further supporting the diagnosis of RA. Also, for both VERA and LERA patients, respectively, the data on joint damage at study start were similar to those published on in”